Tag:

MedImmune

Latest Headlines

Latest Headlines

Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime

Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.

AstraZeneca touts upbeat asthma data for key respiratory candidate

It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.

AstraZeneca's self-styled 'blockbuster' benralizumab tanks in severe COPD study

AstraZeneca was forced to concede a clinical defeat on Monday, noting that one of its top respiratory drugs in the clinic failed a study for severe chronic obstructive pulmonary disease. But while investigators also flagged a higher rate of adverse events for benralizumab than the placebo arm, the pharma giant shows no signs of backing away from a treatment it's billed as a potential $2 billion per year product.

AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown

AstraZeneca has launched a Phase III test of its targeted IL-13 asthma drug tralokinumab, beefing up its late-stage pipeline for respiratory diseases and squaring off against some major league competition now in the clinic.

AstraZeneca rolls out preemie newspaper ads to fight Synagis limits

Drugmakers cheer when influential doctors' groups revise treatment guidelines to include new drugs. But as AstraZeneca's MedImmune unit knows, those groups can backpedal. 

CDC committee recommends AZ's FluMist over flu shot in children

AstraZeneca's flu vaccine sales may have just gotten a boost, courtesy of federal regulators. Wednesday, they recommended that healthy children 2 to 8 years old receive the company's nasal spray flu vaccine FluMist in lieu of flu shots when available.

Roche and MedImmune will concoct lung cancer immunotherapy clinical trial test

Roche's Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer.

AstraZeneca, Bristol-Myers add immuno-oncology collaborations for pipeline stars

With Pfizer pounding on the door amid a full-blown ruckus in Parliament, AstraZeneca took another step forward in its quest to quickly advance its high-profile immuno-oncology program for MEDI4736.

MedImmune inks licensing deal with Bioasis for brain delivery platform

AstraZeneca's MedImmune forged a new deal with Bioasis Technologies, licensing from the Vancouver, Canada, company its brain delivery platform aimed at overcoming challenges associated with the blood-brain barrier.

AstraZeneca signs up for MD Anderson's 'moon-shot' immuno-oncology project

MD Anderson's popular "moon-shot" immuno-oncology research project has won over another big industry player looking to play catch-up in the hottest race in cancer drug R&D. AstraZeneca's biologics arm, MedImmune, has become the latest Big Pharma player to join a team that has already attracted Pfizer and J&J.